Author: Sionna Therapeutics, Inc.

Posted Date:

May 3, 2026

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics, Inc.

May 3, 2026
Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Therapeutics, Inc.

April 30, 2026
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Sionna Therapeutics, Inc.

March 2, 2026
Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences

Sionna Therapeutics, Inc.

February 23, 2026
Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Sionna Therapeutics, Inc.

February 9, 2026